Computational design of enzymatic prophylactics and/or therapeutics for chemical warfare nerve agents
Ended Definitive Contract Awarded Last action
- Contract number
- HDTRA122C0038
- Awardee
-
Arzeda Corp UEI KNSJJT2DJNS1
- Awarding agency
-
Defense Threat Reduction Agency
Department of Defense
- Obligated
- $1,507,784
Award facts
- Contract value 100% obligated
- $1,507,783.93 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Fort Belvoir, VA 22060, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Additional Work (new agreement, FAR part 6 applies) | $389,351 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Original award | $1,118,433 |
About this award
Arzeda Corp, a Seattle-based biotechnology company specializing in artificial intelligence-driven enzyme design, was awarded a $1.51 million Small Business Innovation Research Phase II contract by the Defense Threat Reduction Agency in August 2022. The definitive, firm-fixed-price contract, set aside for small businesses, focuses on the computational design of enzymatic prophylactics and therapeutics specifically targeting chemical warfare nerve agents. Work will be performed at Fort Belvoir, Virginia, with an ultimate completion date of October 9, 2025. This award reflects DTRA's investment in innovative biodefense solutions and demonstrates Arzeda's technical capabilities in developing sophisticated enzymatic countermeasures for national defense applications.
The SBIR Phase II award builds upon Arzeda's demonstrated expertise in advanced protein engineering and bioconversion technologies. The company's broader portfolio includes NSF-funded research on cell-free enzymatic systems for carbon dioxide conversion and biocatalytic processes for sustainable chemical production, positioning the firm as a capable developer of cutting-edge enzymatic solutions. The contract represents a significant research and development effort within the federal biodefense and life sciences sector, leveraging computational biology approaches to address critical national security challenges related to chemical warfare agent mitigation.
Quick answers
Who was awarded contract HDTRA122C0038?
HDTRA122C0038 was awarded to Arzeda Corp by Defense Threat Reduction Agency (Department of Defense) on August 29, 2022.
How much is contract HDTRA122C0038 worth?
The government has obligated $1,507,784 on HDTRA122C0038.
Was contract HDTRA122C0038 competed?
The extent of competition for HDTRA122C0038 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award